/L and age ≥75 years were adverse prognostic factors for OS, Ph+ was not.
impact on the outcome for older patients has declined since the introduction of tyrosine kinase inhibitors (TKI). 5, 6 Due to poor outcome for patients >55 years (according to the Swedish ALL/Acute Leukemia Registries), 10 and based on the promising results of the European Working Group on Adult ALL (EWALL) backbone, 11 this age-adapted protocol (adding TKI in Ph+ ALL) was in- 
| PATIENTS AND METHODS
Every Swedish citizen has a unique social security number, enabling disease surveillance in population-based registries. Patients are reported to the Swedish ALL/Acute Leukemia Registries since 1997, and as previously described, coverage versus the compulsory Swedish Cancer
Registry has been 98%. 10 In this study, patients were identified through Clinical and laboratory data, together with pathology and genetic reports, were verified from medical records by P.K and E.L. Registry data were supplemented in terms of comorbidities, treatment description, and toxicity. Diagnoses were verified by morphology reports, immunophenotyping, and genetics, according to the World Health Organization (WHO) Classification of 2005. 12 Performance status (PS) at diagnosis was reported according to Eastern Cooperative Oncology Group (ECOG) criteria. 13 The comorbidity component (CC) from the adjusted Charlson Comorbidity Index 14 was estimated retrospectively. The ALL diagnosis was not included in the score. Toxicity was assessed retrospectively according to Common Terminology Criteria for Adverse Events. 15 National guidelines for the treatment of patients >55 years, and the main protocols, ABCDV 16 and the EWALL-backbone-based protocol, are shown in the Tables S1 and S2 (the Online Supporting Information) . Allogeneic hSCT in CR1 was recommended for fit patients up to 65 years fulfilling at least one of the following high-risk criteria: white blood cells (WBC) Genetics, other diagnostic evaluations, and toxicity assessments are further described in the Online Supporting Information.
| Statistical methods
For categorical data, differences in proportions were compared using the Chi-square or two-tailed Fischer's exact test, where appropriate.
Continuous variables were compared using the Mann-Whitney U test.
OS was calculated from diagnosis to death, or the date of last follow-up.
Event-free survival (EFS) was estimated from diagnosis to relapse, death, or last follow-up in CR. Event was considered on day one for patients who died without a CR evaluation, or because of refractory disease.
Distributions of OS and EFS were estimated by the Kaplan-Meier method, with differences analyzed using the log-rank test. 
| RESULTS

| Patients in the total population-based ALL cohort
| Patient characteristics
A total of 183 patients were identified via the Swedish ALL /Acute Leukemia Registries. Eleven patients were excluded (one with a blast crisis of chronic myeloid leukemia, two with leukemic phase of follicular lymphoma, two with T-lymphoblastic lymphoma, one with diffuse large B-cell lymphoma, one with T-cell prolymphocytic leukemia, three without a verified ALL diagnosis, and one because of withdrawn consent). Additionally, two patients with ALL were identified through the Swedish Cause of Death Registry. In our cohort of 174 patients B-ALL was the most common phenotype (82%), followed by Burkitt leukemia (11%), and T-ALL (7% 
| Treatment approaches
The majority of patients (80%) were treated with intensive (remission inducing) protocols ( CC values were used in further analyses for comorbidity assessments.
In multivariate analysis (PS, CC, age; logistic regression), only age (as a continuous variable), and proportion of patients with PS ≥2, remained significantly different between the intensive treatment and palliative cohorts (P<.001 and <.05, respectively).
| Overall outcomes
CR was reached for 108/155 (70%) of the entire B-and T-ALL cohort, with 1-and 3-year OS of 50% (95% CI: 42, 58) and 26% (95% CI: 20, 33), respectively.
| Patients with B-and T-ALL treated with remission intention
| Treatment characteristics
Remission inducing therapy was given to 124 patients. The characteristics of these patients and their treatments, for three age-groups, are presented in Table 2 
| Remission rate and survival
The proportion of patients achieving CR (83%) was not influenced by age as continuous variable (odds ratio 0.95, 95% CI: 0.89, 1.03; P=.20), but was lower in the oldest versus youngest age-group (P=.03, Table 2 ).
CR frequency was slightly higher in Ph+ ALL (93% vs 80%; P=.07). No other factors were found to influence the probability of CR achievement (data not shown). Median survival was 16 months (range 0-126).
OS was 59% (95% CI: 50, 67) after 1 year, and estimated to be 32% cohort treated with EWALL-backbone was 49% (95% CI: 32, 65) and 20% (95% CI: 7, 33), respectively. These data for the ABCDV protocol were 63% (95% CI: 53, 74) and 39% (95% CI: 28, 50).
| Patients aged 65-74 years
As a consequence of the new guidelines, a shift from ABCDV before (Figure 1 ).
| Toxicity
| The whole cohort
The proportion of patients affected by toxicity (recorded retrospectively), especially serious infections, was high (Table 2 ). However, it did not differ significantly among the three age-groups, except for renal failure, which was more common in patients aged ≥65 years. 
| According to protocol (EWALL/ABCDV+/-TKI)
Serious infections (mainly septicemia) during induction/consolidation were less common in EWALL-backbone as compared to ABCDVtreated patients [ 
| Allogeneic hSCT in CR1
Allogeneic Table S3 ).
| Prognostic factors
Univariate and multivariate analyses of prognostic factors for OS are shown in Table 3 . The multivariate model revealed that age ≥75 years ( Figure 3A ) and a platelet count (PLT) of ≤35×10 9 /L were negative prognostic factors for OS (Table 3) As compared with the 55-64 y age-group. c As compared with the 65-74 y age-group. d A ratio of serum lactate dehydrogenase versus the upper limit for normal LDH.
after EWALL induction, 39 after ABCDV, and three after other protocols). Detectable MRD1 (>0.1%) had no significant impact on OS or EFS.
| Outcome before and after the introduction of new guidelines
In total, 92 of 155 (59%) patients with B-and T-ALL were diagnosed 
| Palliation
The characteristics of 31 patients are shown in Table 1 
| DISCUSSION
We present a truly population-based study of older and elderly ALL patients which, to our knowledge, is the only publication in the last 20 years 18 describing an unselected cohort including information of cytogenetics and treatments. Low T-ALL and bulky disease but high
Ph+ incidences agree with findings from other studies. 2, 4, [6] [7] [8] [9] As regards therapy, the national guidelines were followed to a large extent.
The decision to refrain from intensive treatment appeared to be based primarily on age and PS, with a minority of patients aged ≥75 years receiving remission induction compared to over 90% of those younger than 75 years. Complete remission rate (83%) after intensive induction was as high as that achieved by other protocols (34%-87%), 2, 3, [6] [7] [8] [9] 19, 20 20 One-year OS in our Ph-EWALL cohort was 46%, compared to 61% in the previously cited abstract. 11 A straightforward comparison of ABCDV and the EWALL-backbone-based protocol in terms of efficacy and toxicity is not justified given that they were used in different (but overlapping) age cohorts. However, when looking at the 65-74 year age-group, where comparable numbers of patients with similar baseline characteristics received each treatment option, we could not see any significant difference in outcome.
An adverse prognostic impact of age in older/elderly patients was demonstrated by us and other authors, 7, 8, 19 but is not universally reported. 6, 9 In epidemiological studies, outcome according to age is striking. 1, 23 Clinical trials often include patients up to 55 or 65 years. Our results suggest that also the 65-74 year group can benefit from intensive chemotherapy. Intensive treatment beyond the 75-year age-limit resulted in low CR rate and low protocol adherence, with almost no possibility of cure. Less intensive chemotherapy ("intensive palliation") in this age-group, inclusive of the use of TKIs for Ph+ disease, seems to be an option, especially as age had a limited impact on outcome in Ph+ ALL. Ph+ disease is classically regarded as a high-risk factor in ALL, 24 inclusive of our national guidelines. However, the introduction of TKIs has challenged this paradigm. 25 We identified a similar OS in Ph-and Ph+ ALL, and a trend toward favorable outcome (compared to Ph-disease) was previously reported in a small Ph+ cohort of elderly patients. 6 In the previously cited Spanish study, older/elderly patients with Ph+ ALL treated with imatinib and a low-intensity protocol had better outcome than those with Ph-ALL receiving EWALL-derived protocol. 20 The hSCT frequency in patients <65 years was high. According to some authors, 4, 26 hSCT in CR1 should be considered for eligible older patients with high-risk features (particularly Ph+). 24 In our study, OS was similar in Ph+ patients treated with chemotherapy+TKI (regardless of treatment intention) and patients receiving hSCT. Even if the number of patients was low, one can speculate whether intensive treatment including hSCT is too toxic for this age-group, as reflected by the high TRM. Low-intensity protocols+TKIs have generated promising results in elderly, 27, 28 and our study indicate that a more restrictive use of hSCT should be considered for older patients with Ph+ ALL.
Thrombocytopenia was associated with impaired OS and EFS. This finding was not reported previously in elderly ALL, but has been noted in a population-based study from Denmark, 23 and in patients treated with hyper-CVAD. 17 In our study, the impaired outcome was not an effect of major hemorrhage, as this affected very few patients. Instead, we interpreted the thrombocytopenia as a pseudo-marker for more aggressive disease.
Notably, survival was impaired for males compared to females in the youngest age-group. Previously reported data on the prognostic significance of sex are conflicting. Historically, male sex was regarded as a negative prognostic factor, mainly in children. In Poland, OS and probability of CR achievement in elderly were found to be superior in females. 7 To speculate, the differences in outcome may be protocol specific, as survival impairment reported for males has disappeared during population-based study periods, 29 as in modern pediatric protocols. 30 Our study has some potential limitations. Toxicity and comorbidity data were collected retrospectively and the prognostic impact of MRD could not be accurately assessed due to lack of measurement in a high proportion of patients achieving CR.
We conclude that the prognosis remains dismal for most older and elderly ALL patients, despite intensive therapy. The use of an ageadapted protocol did not improve outcome in Sweden. Risk factors based on disease and patient characteristics, including age, can probably predict response to intensive treatment. However, Philadelphia positivity is, in the TKI-era, no longer a negative prognostic factor in older/elderly ALL patients. Our finding of an adverse prognostic impact of male sex in patients aged 55-65 years warrants further investigation. Intensive treatment should primarily be reserved for patients aged <75 years. The challenge remains to decrease early mortality and the frequency of relapse. Novel treatment modalities are urgently needed for elderly ALL patients.
